A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Combretastatin A1 (OXi4503) is a dual-function drug with vascular disrupting and cytotoxic properties that has exhibited single-agent anti-leukemia activity in murine xenograft models of acute myeloid leukemia (AML) and in a prior Phase 1A clinical study for relapsed/refractory (R/R) AML. The purpos...

Full description

Bibliographic Details
Main Authors: Fatih M. Uckun, Christopher R. Cogle, Tara L. Lin, Sanjive Qazi, Vuong N. Trieu, Gary Schiller, Justin M. Watts
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:Cancers
Subjects:
aml
combretastatin
leukemia
clinical study
oxa
Online Access:https://www.mdpi.com/2072-6694/12/1/74

Internet

https://www.mdpi.com/2072-6694/12/1/74

Similar Items